

Respiratory Syncytial Virus Enrollment Form

CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-864-7860.

Provider Help Desk: 1-866-408-6132 (Hoosier Healthwise)

1-844-533-1995 (Healthy Indiana Plan)

1-844-284-1798 (Hoosier Care Connect)

Today's D	ate		
Month	Day	Year	

Note: This form must be completed by the prescribing provider.

All sections must be completed or the request will be returned

Patient's Medicaid #	Date of Birth:		
Patient Name:	Prescriber's Name:		
Prescriber's IN License #:	Specialty		
Prescriber's NPI #:	Prescriber's Signature:		
Return Fax #:	Return Phone #:		
Check box if requesting retro-active PA: \Box	Date(s) of service requested for retro-active eligibility (if applicable):		
Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility ti			

Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility timelines) with dates of service prior to 30 calendar days of submission separately from current PA requests (dates of service 30 calendar days or less and going forward).

https://providers.anthem.com/in

Anthem Blue Cross and Blue Shield is the trade name of Anthem Insurance Companies, Inc., independent licensee of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

Providers who are contracted with Anthem Blue Cross and Blue Shield to serve Hoosier Healthwise, Healthy Indiana Plan and Hoosier Care Connect through an accountable care organization (ACO), participating medical group (PMG) or Independent Physician Association (IPA) are to follow guidelines and practices of the group. This includes but is not limited to authorization, covered benefits and services, and claims submittal. If you have questions, please contact your group administrator or your Anthem network representative. INBCBS-CD-027498-23 June 2023

1. Patient information		
Actual gestational age:	weeks	days
Current age (must be < 24 months): months	Current weight:	□ kg □ lb
2. Prescription information		
☐ Inject 15 mg/kg IM once per month throug	h March 31	
□ Other:	_	
3. Palivizumab Prior Approval Criteria G granted under any of the following cir		five (5) doses (approval will be
☐ Infants < 12 months of age born preterm b	pefore 32 weeks gestation	
☐ Infants < 12 months of age born with chro (BPD) (defined as an oxygen requirement fo oxygen requirement)		
Please provide dates of oxygen suppleme	entation:	
☐ Infants < 12 months of age and requiring disease or cardiomyopathies	medical therapy for hemodyna	mically significant heart
Please provide relevant diagnoses/medic	ation intervention:	
☐ Infants < 12 months of age with neuromus	scular disease or congenital ab	onormalities of the airways
Please provide relevant diagnoses:		

☐ Infants and children < 24 months of age who required at least 28 days of supplemental oxygen after birth, and continue to require medical intervention (supplemental oxygen, chronic corticosteroid use, diuretic therapy)
Please provide dates of oxygen supplementation/medication intervention:
□ Infants and children < 24 months of age who will be profoundly immunocompromised during the RSV season (solid organ or hematopoietic stem cell transplant, chemotherapy, or other condition that leaves the infant or child profoundly immunocompromised, including those awaiting heart transplant)
Please Explain:
☐ Infants and children < 24 months of age with evidence of hemodynamically significant coronary heart disease, cardiomyopathies, or pulmonary hypertension
☐ Infants and children < 24 months of age with evidence of hemodynamically significant coronary heart

Note: Prophylaxis will be given only until the infant or child reaches a maximum of five (5) doses or the end of the RSV season, whichever comes first.

The Respiratory Syncytial Virus (RSV) season is defined as November 1st through March 31st. The Office of Medicaid Policy & Planning may extend the season based on statewide virology data. Administration of additional doses will require separate prior authorization. [Please note that the criterion presented on the form pertains to the <Indiana Health Coverage Programs>/<Plan Name> pharmacy benefit only].

CONFIDENTIAL INFORMATION

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation.

If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents